Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Brown

Psychiatry Raleigh, NC Medical Doctor

NPI 1841274396 CMS profile 501240

1500 Sunday Dr, Suite #200, Raleigh, NC 27607

Open in the dashboard

General payments

$3,885

245 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Brown of Raleigh, NC is reported in the CMS Open Payments database as having received $3,885 across 245 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,082 70
2024 General $777 43
2023 General $262 14
2022 General $15 1
2021 General $16 1
2020 General $377 18
2019 General $1,357 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Brown
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to James Brown were reported at $1,082. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year James Brown Psychiatry median Middle half National median
2019 $1,357 $184 $59–$605 $163
2020 $377 $119 $36–$372 $114
2021 $16 $143 $43–$576 $132
2022 $15 $153 $50–$590 $149
2023 $262 $170 $56–$651 $160
2024 $777 $179 $57–$673 $164
2025 $1,082 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch Health US, LLC $494 38 payments
  2. AbbVie, Inc. $402 21 payments
  3. Otsuka America Pharmaceutical, Inc. $366 18 payments
  4. Janssen Pharmaceuticals, Inc $341 19 payments
  5. Axsome Therapeutics, Inc. $290 21 payments
  6. Supernus Pharmaceuticals, Inc. $265 22 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $205 14 payments
  8. Lundbeck LLC $145 8 payments
  9. Allergan Inc. $129 17 payments
  10. Ironshore Pharmaceuticals Inc. $129 7 payments
  11. Other $1,120 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,885 245 payments
Products named General payments · program years 2019–2025
  1. APLENZIN $494 38 payments
  2. VRAYLAR Neuroscience $364 29 payments
  3. REXULTI $347 17 payments
  4. WELLBUTRIN Neurology $327 22 payments
  5. Auvelity $290 21 payments
  6. Qelbree $265 22 payments
  7. WELLBUTRIN Neurology $167 16 payments
  8. VRAYLAR Neuroscience $154 8 payments
  9. INVEGA TRINZA $144 8 payments
  10. SPRAVATO $143 8 payments
  11. Other $1,934 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

176

Median for Psychiatry: 574

Drug cost

$3,783

Median for Psychiatry: $27,624

Branded share of claims

29.5%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 28 $1,434
Lurasidone Hcl Generic 15 $742
Fluoxetine Hcl Generic 35 $560
Bupropion Xl Bupropion Hcl Brand 24 $281
Alprazolam Generic 28 $232
Escitalopram Oxalate Generic 14 $198
Clonazepam Generic 17 $195
Sertraline Hcl Generic 15 $141

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$5,202

Medicare's payments for the services billed

Medicare patients

13

Average age 63

Services billed

86

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $148
$148 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $66
  • Lundbeck LLC $60
$125 — —
VRAYLAR
  • AbbVie, Inc. $104
$104 — —
CAPLYTA
  • ITI, Inc. $84
$84 — —
Equetro
  • Validus Pharmaceuticals LLC $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

245 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record